Grunnleggende statistikk
| CIK | 1647320 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Clementia Pharmaceuticals Inc.
SEC Filings (Chronological Order)
På denne siden finner du en fullstendig, kronologisk liste over SEC-arkiveringer, med unntak av eierskaps-arkiveringer som vi leverer andre steder.
| April 29, 2019 |
CMTA / Clementia Pharmaceuticals Inc. 15-12B 15-12B 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-38177 CLEMENTIA PHARMACEUTICALS INC. (Exact name of registrant a |
|
| April 18, 2019 |
CMTA / Clementia Pharmaceuticals Inc. S-8 POS As filed with the Securities and Exchange Commission on April 18, 2019 Registration No. |
|
| April 18, 2019 |
CMTA / Clementia Pharmaceuticals Inc. POS AM As filed with the Securities and Exchange Commission on April 18, 2019 Registration No. |
|
| April 18, 2019 |
Ipsen Completes Acquisition of Clementia Pharmaceuticals Exhibit 99.1 PRESS RELEASE Ipsen Completes Acquisition of Clementia Pharmaceuticals · Ipsen’s Rare Diseases portfolio significantly enhanced with late-stage drug candidate, palovarotene, for the treatment of rare bone disorders in adult and pediatric patients · Transaction reinforces Ipsen’s strong commitment to providing life-altering treatments to patients with high unmet medical needs Paris, 18 |
|
| April 18, 2019 |
CMTA / Clementia Pharmaceuticals Inc. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2019 Commission File Number: 001-38177 Clementia Pharmaceuticals Inc. (Translation of registrant’s name into English) 1000 de la Gauchetiere Street West, Suite 1200 Montreal, Quebec, Canada |
|
| April 11, 2019 |
EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A. MONTREAL, April 11, 2019 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (Nasdaq: CMTA) ("Clementia" or the "Corporation") is pleased to announce that the Québec Superior Court issued earlier today a final order approving the previously |
|
| April 11, 2019 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2019 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 1000 de la Gauchetiere Street West, Suite 1200 Montreal, Quebec, CAN |
|
| April 9, 2019 |
Clementia Pharmaceuticals Inc. Shareholders Approve Plan of Arrangement With Ipsen S.A. EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Clementia Pharmaceuticals Inc. Shareholders Approve Plan of Arrangement With Ipsen S.A. MONTREAL, April 09, 2019 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (Nasdaq: CMTA) ("Clementia" or the "Corporation") is pleased to announce that its shareholders have approved the previously announced statutory plan of arrangement under the Canada Business |
|
| April 9, 2019 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2019 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 1000 de la Gauchetiere Street West, Suite 1200 Montreal, Quebec, CAN |
|
| March 29, 2019 |
Office Lease Agreement with Hines Global Reit Riverside Center LLC dated February 13, 2019. Exhibit 10.18 RIVERSIDE CENTER TWO RIVERSIDE CENTER NEWTON, MASSACHUSETTS OFFICE LEASE AGREEMENT BETWEEN HINES GLOBAL REIT RIVERSIDE CENTER, LLC, a Delaware limited liability company (“LANDLORD”) AND CLEMENTIA PHARMACEUTICALS USA, INC., a Delaware corporation (“TENANT”) OFFICE LEASE AGREEMENT THIS OFFICE LEASE AGREEMENT (this “Lease”) is made and entered into as of February 13, 2019, by and betwee |
|
| March 29, 2019 |
Third Amended and Restated Employment Agreement with Clarissa Desjardins. Exhibit 10.12 |
|
| March 29, 2019 |
Amended and Restated Employment Agreement with Steve Forte. Exhibit 10.13 |
|
| March 29, 2019 |
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer Exhibit 12.1 CERTIFICATION I, Clarissa Desjardins, certify that: 1. I have reviewed this annual report on Form 20-F of Clementia Pharmaceuticals Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleadin |
|
| March 29, 2019 |
Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer Exhibit 12.2 CERTIFICATION I, Steve Forte, certify that: 1. I have reviewed this annual report on Form 20-F of Clementia Pharmaceuticals Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with r |
|
| March 29, 2019 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with this annual report on Form 20-F of Clementia Pharmaceuticals Inc. (the “Company”) for the fiscal year ended December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steve Forte, Chief Financial Off |
|
| March 29, 2019 |
Agreement of Sub-Sublease with Analysis Group LTD, dated December 10, 2018. Exhibit 10.17 SUB-SUBLEASE AGREEMENT OF SUB-SUBLEASE (the “Sub-Sublease Agreement”), dated the 10 day of December 2018 by and between ANALYSIS GROUP LTD., having its head office at 1000 De La Gauchetière Street West, Suite 1200, in the City of Montreal, Province of Quebec, H3B 4W5 (hereinafter referred to as (“Sub-Sublandlord”) and CLEMENTIA PHARMACEUTICALS INC., having currently an office at 4150 |
|
| March 29, 2019 |
CMTA / Clementia Pharmaceuticals Inc. FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 29, 2019 |
Amended and Restated Employment Agreement with Jeff Packman. Exhibit 10.15 |
|
| March 29, 2019 |
Exhibit 10.6 AMENDMENT NO. 1 TO THE EXCLUSIVE LICENSE AGREEMENT This Amendment No. 1 (this “Amendment”) to the Exclusive License Agreement dated March 29, 2017 (the “Agreement”), is executed as of 07 December, 2018 (the “Amendment Effective Date”), by and between Galderma Research & Development SNC, a société en nom collectif organized under the laws of France having its principal address at Les T |
|
| March 29, 2019 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with this annual report on Form 20-F of Clementia Pharmaceuticals Inc. (the “Company”) for the fiscal year ended December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Clarissa Desjardins, President a |
|
| March 29, 2019 |
Exhibit 10.5 |
|
| March 29, 2019 |
Amended and Restated Employment Agreement with Donna Grogan. Exhibit 10.14 |
|
| March 13, 2019 |
Exhibit 99.1 Exhibit 99.1 These materials are important and require your immediate attention. They require shareholders of Clementia Pharmaceuticals Inc. to make important decisions. If you are in doubt as to how to make such decisions, please contact your financial, legal, tax or other professional advisors. If you are a holder of Shares and have any questions or require more information with reg |
|
| March 13, 2019 |
Filed by e3 Filing, Computershare 1-800-973-3274 - Clementia Pharmaceuticals Inc. - Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2019 Commission File Number: 001-38177 Clementia Pharmaceuticals Inc. (Translation of registrant’ |
|
| March 13, 2019 |
Exhibit 99.3 Exhibit 99.3 THE INFORMATION CIRCULAR AND INSTRUCTIONS ACCOMPANYING THIS LETTER OF TRANSMITTAL SHOULD BE READ CAREFULLY BEFORE THIS LETTER OF TRANSMITTAL IS COMPLETED. LETTER OF TRANSMITTAL FOR REGISTERED HOLDERS OF COMMON SHARES OF CLEMENTIA PHARMACEUTICALS INC. This Letter of Transmittal, properly completed and duly executed by the registered holder (“Shareholder”) of common shares |
|
| March 13, 2019 |
Exhibit 99.2 Exhibit 99.2 8th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 www.computershare.com Security Class Holder Account Number Form of Proxy - Special Meeting to be held on April 9, 2019 This Form of Proxy is solicited by and on behalf of Management. Notes to proxy 1. Every holder has the right to appoint some other person or company of their choice, who need not be a holder, to at |
|
| March 13, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Clementia Pharmaceuticals Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 185575107 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, |
|
| March 6, 2019 |
Exhibit 99.2 SUPPORT AND VOTING AGREEMENT THIS AGREEMENT is made as of March 2, 2019. BETWEEN: BDC CAPITAL INC., a corporation existing under the Canada Business Corporations Act ("Shareholder") - and - 11188291 Canada Inc., a corporation existing under the Canada Business Corporations Act ("Purchaser") - and - IPSEN S.A., a société anonyme existing under the Laws of France ("Guarantor") WHEREAS S |
|
| March 6, 2019 |
Exhibit 99.3 SUPPORT AND VOTING AGREEMENT THIS AGREEMENT is made as of March 4, 2019. BETWEEN: NEW ENTERPRISE ASSOCIATES 15, L.P., a limited partnership existing under the laws of Delaware ("Shareholder") - and - 11188291 Canada Inc., a corporation existing under the Canada Business Corporations Act ("Purchaser") - and - IPSEN S.A., a société anonyme existing under the Laws of France ("Guarantor") |
|
| March 6, 2019 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2019 Commission File Number: 001-38177 Clementia Pharmaceuticals Inc. (Translation of registrant’s name into English) 4150 Sainte-Catherine Street West, Suite 550 Montreal, Quebec, Canada H3 |
|
| March 6, 2019 |
Exhibit 99.1 CLEMENTIA PHARMACEUTICALS INC. OBTAINS INTERIM ORDER FOR PROPOSED TRANSACTION WITH IPSEN S.A. AND ENTERS INTO SUPPORT AND VOTING AGREEMENTS WITH TWO ADDITIONAL SIGNIFICANT SHAREHOLDERS MONTREAL, QUÉBEC, CANADA - March 6, 2019 – Clementia Pharmaceuticals Inc. (Nasdaq: CMTA) is pleased to announce that it has obtained an interim order from the Québec Superior Court in connection with th |
|
| March 6, 2019 |
EX-99.1.01 EXHIBIT 1.01 CUSIP No. 185575107 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing of the Schedule 13D to which this Agreement is attached. Dated: March 6, 2019 IPSEN S.A. By: /s/ David Meek Name: David Meek Title: Chief Executive Officer 11188291 CANADA INC. By: /s/ Francois Garnier Name: Francois Garnier Title: President |
|
| March 6, 2019 |
CMTA / Clementia Pharmaceuticals Inc. / Ipsen, S.a. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Clementia Pharmaceuticals Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 185575107 (CUSIP Number) Ipsen S.A. 65, quai Georges Gorse Boulogne Billancourt 92650 France Attn: General Counsel +33 (0) 1 58 33 50 00 with a copy to: Goodwi |
|
| March 1, 2019 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated March 1, 2019 (the “Schedule 13D”), with respect to the Common Shares of Clementia Pharmaceuticals, Inc. |
|
| March 1, 2019 |
CMTA / Clementia Pharmaceuticals Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 4 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* CLEMENTIA PHARMACEUTICALS INC. (Name of Issuer) COMMON SHARES (Title of Class of Securities) 185575107 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP IV LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Addr |
|
| February 28, 2019 |
Exhibit 99.1 Exhibit 99.1 1500 Robert-Bourassa Blvd., February 27, 2019 7th Floor Montreal QC, H3A 3S8 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: Clementia Pharmaceuticals Inc. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Special Meeting Record Date for Notice of Mee |
|
| February 28, 2019 |
Filed by e3 Filing, Computershare 1-800-973-3274 - Clementia Pharmaceuticals Inc. - Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2019 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of regi |
|
| February 26, 2019 |
EXHIBIT 99.1 Clementia Announces Cancellation of Fourth Quarter and Year-End 2018 Financial Results and Conference Call MONTREAL, Feb. 26, 2019 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that the company will not report its fourth qua |
|
| February 26, 2019 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2019 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 1000 de la Gauchetiere Street West, Suite 1200 Montreal, Quebec, |
|
| February 25, 2019 |
EX-99.3 4 tv511286ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 SUPPORT AND VOTING AGREEMENT THIS AGREEMENT is made as of February 24, 2019. BETWEEN: ORBIMED PRIVATE INVESTMENTS IV, LP, a limited partnership existing under the laws of Delaware ("Shareholder") - and - 11188291 CANADA INC., a corporation existing under the Canada Business Corporations Act ("Purchaser") - and - IPSEN S.A., a société anonyme e |
|
| February 25, 2019 |
Exhibit 99.2 11188291 CANADA INC. as Purchaser and IPSEN S.A. as Guarantor and CLEMENTIA PHARMACEUTICALS INC. as Corporation ARRANGEMENT AGREEMENT February 24, 2019 TABLE OF CONTENTS Article 1 Interpretation 1 Section 1.1 Defined Terms 1 Section 1.2 Certain Rules of Interpretation 19 Section 1.3 Schedules 20 Article 2 The Arrangement 20 Section 2.1 Arrangement 20 Section 2.2 Interim Order 20 Secti |
|
| February 25, 2019 |
Exhibit 99.4 SUPPORT AND VOTING AGREEMENT THIS AGREEMENT is made as of February 24, 2019. BETWEEN: [●] ("Shareholder") - and - 11188291 CANADA INC., a corporation existing under the Canada Business Corporations Act ("Purchaser") - and - IPSEN S.A., a société anonyme existing under the Laws of France ("Guarantor") WHEREAS Shareholder is the beneficial owner of [●] common shares and [●] options to a |
|
| February 25, 2019 |
FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company Clementia Pharmaceuticals Inc. (the "Company") 4150 Ste-Catherine Street West, Suite 550 Montreal, QC H3Z 2Y5 Item 2 Date of Material Change February 24, 2019 Item 3 News Release A joint press release describing the material change was issued by the Company and Ipsen S.A. ("Ipsen") and was disseminated via Reuters |
|
| February 25, 2019 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2019 Commission File Number: 001-38177 Clementia Pharmaceuticals Inc. (Translation of registrant’s name into English) 4150 Sainte-Catherine Street West, Suite 550 Montreal, Quebec, Canada |
|
| February 25, 2019 |
Exhibit 99.1 PRESS RELEASE Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio · Clementia’s late-stage drug candidate, palovarotene, has rare pediatric disease and breakthrough therapy designations for the treatment of an ultra-rare bone disorder and a path to approval in 2020 · Acquisition to transform Ipsen’s Rare Disease portfolio by leveraging Clementia’s |
|
| February 25, 2019 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2019 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant’s name into English) 4150 Sainte-Catherine Street West, Suite 550 Montreal, Quebec, Canad |
|
| February 20, 2019 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2019 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 1000 de la Gauchetiere Street West, Suite 1200 Montreal, Quebec, |
|
| February 20, 2019 |
EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Clementia Announces Date of Fourth Quarter and Full Year 2018 Results and Presentation at 8th Annual SVB Leerink Global Healthcare Conference MONTREAL, Feb. 20, 2019 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other dis |
|
| February 13, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Clementia Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 185575107 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 13, 2019 |
EX-99.1 2 tv511659ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Clementia Pharmaceuticals Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. February 13, 2019 BAKER BROS. |
|
| February 13, 2019 |
CMTA / Clementia Pharmaceuticals Inc. / Baker Brothers Advisors LP - SC 13G Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2019 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Clementia Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 185575107 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| February 11, 2019 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2019 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal ex |
|
| February 11, 2019 |
EXHIBIT 99.1 Clementia Granted Rare Pediatric Disease Designation by FDA for Palovarotene for Fibrodysplasia Ossificans Progressiva MONTREAL, Feb. 11, 2019 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that the U.S. Food and Drug Adminis |
|
| November 30, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal ex |
|
| November 30, 2018 |
Clementia Announces the Departure of Chief Commercial Officer EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Clementia Announces the Departure of Chief Commercial Officer MONTREAL, Nov. 30, 2018 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced the departure of Eric Grinstead as the Company’s chief co |
|
| November 21, 2018 |
Clementia to Present at the Evercore ISI HealthCONx Conference EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Clementia to Present at the Evercore ISI HealthCONx Conference MONTREAL, Nov. 21, 2018 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that Clarissa Desjardins, Ph.D., chief executive officer |
|
| November 21, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal ex |
|
| November 7, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2018 Commission File Number 001-38177 Clementia Pharmaceuticals Inc. (Translation of registrant’s name into English) 4150 St Catherine Street West, Suite 550 Montreal, Quebec, Canada, H3Z 2Y5 (Address |
|
| November 7, 2018 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following management’s discussion and analysis (MD&A) of our financial condition and results of operations was prepared by Management with information available as at November 6, 2018. This MD&A should be read in conjunction with our unaudited interim condensed consolidated financial statements f |
|
| November 7, 2018 |
Clementia Pharmaceuticals Inc. EX-99.2 3 exh992p.htm EXHIBIT 99.2 Exhibit 99.2 Clementia Pharmaceuticals Inc. Interim Condensed Consolidated Financial Statements Three and nine-month periods ended September 30, 2018 and 2017 (unaudited) Clementia Pharmaceuticals Inc. Interim Condensed Consolidated Statements of Financial Position (unaudited) As at (in US dollars) Note September 30, 2018 December 31, 2017 Assets Current assets C |
|
| November 7, 2018 |
EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Clementia Reports Third Quarter 2018 Operating Results and Pipeline Updates Recent FDA Meeting Identifies Path Towards NDA Submission in the Second Half of 2019 Financing Raises $75 million to Support a Potential Commercial Launch MONTREAL, Nov. 07, 2018 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), a clinical-stage biopharmaceuti |
|
| November 7, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal ex |
|
| November 5, 2018 |
CMTA / Clementia Pharmaceuticals Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* CLEMENTIA PHARMACEUTICALS INC. (Name of Issuer) COMMON SHARES (Title of Class of Securities) 185575107 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP IV LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Addr |
|
| November 5, 2018 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated November 5, 2018 (the “Schedule 13D”), with respect to the Common Shares of Clementia Pharmaceuticals, Inc. |
|
| October 30, 2018 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-227726 Prospectus Supplement (To Prospectus dated October 18, 2018) 5,300,000 Common Shares We are offering 5,300,000 of our common shares pursuant to this prospectus supplement. Our outstanding common shares are listed for trading on The Nasdaq Global Select Market under the symbol “CMTA.” On October 29, 2018, the closing sales price of our co |
|
| October 30, 2018 |
5,300,000 Shares CLEMENTIA PHARMACEUTICALS INC. COMMON SHARES UNDERWRITING AGREEMENT Exhibit 1.1 5,300,000 Shares CLEMENTIA PHARMACEUTICALS INC. COMMON SHARES UNDERWRITING AGREEMENT October 29, 2018 October 29, 2018 Morgan Stanley & Co. LLC Leerink Partners LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Leerink Partners LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Clementia Pharmaceuticals Inc., a corporati |
|
| October 30, 2018 |
CMTA / Clementia Pharmaceuticals Inc. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 October 29, 2018 Commission File Number: 001-38177 CLEMENTIA PHARMACEUTICALS INC. Clementia Pharmaceuticals Inc. 4150 Sainte-Catherine Street West, Suite 550 Montreal, Quebec, Canada H3Z 2Y5 (514) 940-3600 (Addres |
|
| October 30, 2018 |
Clementia Announces Pricing of Public Offering of Common Shares Clementia Announces Pricing of Public Offering of Common Shares MONTREAL, Oct. 29, 2018 – Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced the pricing of an underwritten public offering of 5,300,000 common shares at the price of $13.25 per share before underw |
|
| October 29, 2018 |
Clementia Announces Proposed Public Offering of Common Shares EXHIBIT 99.1 Clementia Announces Proposed Public Offering of Common Shares MONTREAL, Oct. 29, 2018 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that it intends to offer and sell, subject to market conditions, $50,000,000 of its common s |
|
| October 29, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal exe |
|
| October 29, 2018 |
SUBJECT TO COMPLETION, PRELIMINARY PROSPECTUS SUPPLEMENT DATED OCTOBER 29, 2018 Filed Pursuant to Rule 424(b)(5) Registration No. 333-227726 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting offers to buy these securiti |
|
| October 23, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) 6-K 1 f6k102318.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite |
|
| October 23, 2018 |
EXHIBIT 99.1 Clementia Announces Plan to Submit a New Drug Application for Palovarotene for the Treatment of FOP Based on Positive Phase 2 Results Updated Regulatory Strategy Based on 12-Week Flare-up Data from Completed Phase 2 Program and Consultation with the FDA NDA Submission Planned for the Second Half of 2019 MONTREAL, Oct. 23, 2018 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (Nasdaq: |
|
| October 22, 2018 |
CLEMENTIA PHARMACEUTICALS INC. $40,000,000 of Common Shares (No par value per share) SALES AGREEMENT Exhibit 10.1 CLEMENTIA PHARMACEUTICALS INC. $40,000,000 of Common Shares (No par value per share) SALES AGREEMENT October 19, 2018 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Clementia Pharmaceuticals Inc., a corporation incorporated under the Canada Business Corporations Act (the “Company”), confirms its agreement (this “Agreement”) |
|
| October 22, 2018 |
CMTA / Clementia Pharmaceuticals Inc. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2018 (Report No. 2) Commission File Number: 001-38177 CLEMENTIA PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) 4150 Sainte-Catherine Street West, Suite |
|
| October 22, 2018 |
Up to $40,000,000 Common Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-227726 Prospectus Supplement (To Prospectus dated October 18, 2018) Up to $40,000,000 Common Shares We have entered into a sales agreement, or the Sales Agreement, with Leerink Partners LLC, or Leerink, dated October 19, 2018, relating to our common shares, no par value, offered by this prospectus supplement and the accompanying prospectus. In |
|
| October 16, 2018 |
CMTA / Clementia Pharmaceuticals Inc. CORRESP October 16, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street, N. |
|
| October 5, 2018 |
CMTA / Clementia Pharmaceuticals Inc. F-3 As filed with the Securities and Exchange Commission on October 5, 2018 Registration No. |
|
| October 2, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal exe |
|
| October 2, 2018 |
EXHIBIT 99.1 Clementia Initiates Phase 1 Clinical Trial of Palovarotene Eye Drop Formulation in Healthy Volunteers Data from Study Expected in Q1 2019 MONTREAL, Oct. 02, 2018 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced the initiation o |
|
| September 26, 2018 |
EXHIBIT 99.1 Clementia Announces Updated Phase 2 Part B Data on Palovarotene for FOP Updated 12-Week Flare-Up Data Presented at Mechanistic and Therapeutic Advances in Rare Skeletal Diseases and ASBMR 2018 Company Announces Additional Updated 12-Month WBCT Scan Data Data Continue to Support Treatment Potential of Palovarotene for People with FOP MONTREAL, Sept. 26, 2018 (GLOBE NEWSWIRE) - Clementi |
|
| September 26, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal e |
|
| September 5, 2018 |
Clementia to Present at ASBMR 2018 and Upcoming Investor Conferences EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Clementia to Present at ASBMR 2018 and Upcoming Investor Conferences MONTREAL, Sept. 05, 2018 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced the company’s participation at the following upco |
|
| September 5, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal e |
|
| August 16, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal exec |
|
| August 16, 2018 |
EXHIBIT 99.1 Clementia Announces Completion of Enrollment in Phase 3 MOVE Trial for FOP Enrollment Completed Four Months Ahead of Schedule; Two Interim Data Analyses On Track for 2019 MONTREAL, Aug. 16, 2018 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), a clinical-stage company innovating treatments for individuals with ultra-rare bone disorders and other diseases, today announ |
|
| August 9, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2018 Commission File Number 001-38177 Clementia Pharmaceuticals Inc. (Translation of registrant’s name into English) 4150 St Catherine Street West, Suite 550 Montreal, Quebec, Canada, H3Z 2Y5 (Address of |
|
| August 9, 2018 |
Clementia Pharmaceuticals Inc. Exhibit 99.2 Clementia Pharmaceuticals Inc. Interim Condensed Consolidated Financial Statements Three and six-month periods ended June 30, 2018 and 2017 (unaudited) Clementia Pharmaceuticals Inc. Interim Condensed Consolidated Statements of Financial Position (unaudited) As at (in US dollars) Note June 30, 2018 December 31, 2017 Assets Current assets Cash $ 12,937,235 $ 36,230,343 Short-term inves |
|
| August 9, 2018 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following management’s discussion and analysis (MD&A) of our financial condition and results of operations was prepared by Management with information available as at August 8, 2018. This MD&A should be read in conjunction with our unaudited interim condensed consolidated financial statements for |
|
| August 9, 2018 |
EXHIBIT 99.1 Clementia Reports Second Quarter 2018 Operating Results and Pipeline Updates Patient Enrollment in Phase 3 MOVE Trial of Palovarotene for FOP On Track; Two Interim Data Analyses Expected in 2019 MONTREAL, Aug. 09, 2018 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone d |
|
| August 9, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal exec |
|
| July 13, 2018 |
Clementia Appoints Experienced Financial Executive Steve Forte as Chief Financial Officer EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Clementia Appoints Experienced Financial Executive Steve Forte as Chief Financial Officer MONTREAL, July 13, 2018 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases, today announced the appointment of experie |
|
| July 13, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal execut |
|
| July 5, 2018 |
EXHIBIT 99.1 Clementia Appoints Industry Executive Shawn Tomasello to its Board of Directors Accomplished Biopharma Leader Brings Over 30 Years of Experience Leading Strategic and Commercial Efforts MONTREAL, July 05, 2018 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders a |
|
| July 5, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal execut |
|
| May 31, 2018 |
Exhibit 99.1 CLEMENTIA PHARMACEUTICALS INC. ANNUAL MEETING OF SHAREHOLDERS MONTRÉAL QUÉBEC, CANADA TUESDAY, MAY 29, 2018 REPORT OF VOTING RESULTS In accordance with section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations, the following sets out the matters voted on at the annual meeting of shareholders (the "Meeting") of Clementia Pharmaceuticals Inc. (the "Corporation") hel |
|
| May 31, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2018 Commission File Number 001-38177 Clementia Pharmaceuticals Inc. (Translation of registrant’s name into English) 4150 St Catherine Street West, Suite 550 Montreal, Quebec, Canada, H3Z 2Y5 (Address of pr |
|
| May 31, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal executi |
|
| May 31, 2018 |
Clementia to Present at the Jefferies 2018 Global Healthcare Conference EXHIBIT 99.1 Clementia to Present at the Jefferies 2018 Global Healthcare Conference MONTREAL, May 31, 2018 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases, today announced that Clarissa Desjardins, Ph.D., chief executive officer and founder of Clementi |
|
| May 23, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal executi |
|
| May 23, 2018 |
EXHIBIT 99.1 Clementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOP Statistically Significant 91% Reduction of New HO at Flare-up Sites at 12 Weeks; 65% Reduction of New HO at 12-Month WBCT Scan Evaluable Patients with No New Bone at 12 Weeks Had No New Bone at 12 Months Company to Host Conference Call Today at |
|
| May 9, 2018 |
Clementia Pharmaceuticals Inc. Exhibit 99.2 Clementia Pharmaceuticals Inc. Interim Condensed Consolidated Financial Statements Three-months ended March 31, 2018 and 2017 (unaudited) Clementia Pharmaceuticals Inc. Interim Condensed Consolidated Statements of Financial Position (unaudited) As at (in US dollars) Note March 31, 2018 December 31, 2017 Assets Current assets Cash $ 26,638,487 $ 36,230,343 Short-term investments 4 30,0 |
|
| May 9, 2018 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS EX-99.1 2 exh991.htm EXHIBIT 99.1 Exhibit 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following management’s discussion and analysis (MD&A) of our financial condition and results of operations was prepared by Management with information available as at May 8, 2018. This MD&A should be read in conjunction with our unaudited interim condensed consol |
|
| May 9, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2018 Commission File Number 001-38177 Clementia Pharmaceuticals Inc. (Translation of registrant’s name into English) 4150 St Catherine Street West, Suite 550 Montreal, Quebec, Canada, H3Z 2Y5 (Address of pr |
|
| May 9, 2018 |
EXHIBIT 99.1 Clementia Reports First Quarter 2018 Operating Results and Pipeline Updates On Track to Report Data from Part B of its Phase 2 Study of Palovarotene for Fibrodysplasia Ossificans Progressiva This Quarter Enrollment in Phase 3 MOVE Trial On Track, Phase 2 MO-Ped Trial Underway MONTREAL, May 09, 2018 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage bioph |
|
| May 9, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal executi |
|
| May 2, 2018 |
Exhibit 99.1 Innovating New Treatments for People with Ultra - rare Bone Disorders and Other Diseases Clementia Annual Report 2017 Innovating New Treatments for People with Ultra - rare Bone Disorders and Other Diseases Letter to our Shareholders 2017 To our shareholders, It was less than 10 years ago when I first learned about fibrodysplasia ossificans progressiva, or FOP, during a conversation with |
|
| May 2, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal executi |
|
| May 2, 2018 |
Exhibit 99.1 NOTICE OF ANNUAL MEETING OFSHAREHOLDERS To the shareholders of Clementia Pharmaceuticals Inc. (the"Company"): NOTICEISHEREBYGIVENTHATtheannualmeetingoftheshareholders(the"Meeting")oftheCompanywillbeheld attheofficesofDentonsCanadaLLP,locatedat1,PlaceVille-Marie,Suite3900,Montreal,Quebec,H3B4M7, Canada,onMay29,2018at10:00a.m.,forthefollowingpurposes: 1. Toreceivetheauditedfinancialstat |
|
| May 2, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal executi |
|
| May 2, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal executi |
|
| May 2, 2018 |
Exhibit 99.1 SecurityClass Holder AccountNumber Form of Proxy -Annual General Meeting to be held on May 29,2018 This Form of Proxy is solicited by and on behalf ofManagement. Notes toproxy 1. Every holder has the right to appoint some other person or company of their choice, who need not be a holder, to attend and act on their behalf at the meeting or any adjournment or postponement thereof. If yo |
|
| April 20, 2018 |
EXHIBIT 99.1 Clementia Initiates Phase 2 MO-Ped Trial for Palovarotene in Patients with Multiple Osteochondromas Global, Late-stage Trial for Ultra-rare Skeletal Disease with No Approved Treatments MONTREAL, April 20, 2018 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage company innovating new treatments for people with ultra-rare bone disorders and other diseases, |
|
| April 20, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal execu |
|
| March 23, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal execu |
|
| March 23, 2018 |
To: All Canadian Securities Regulatory Authorities EX-99.1 2 exh991.htm EXHIBIT 99.1 Exhibit 99.1 1500 Robert-Bourassa Blvd., March 23, 2018 7th Floor Montreal QC, H3A 3S8 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: Clementia Pharmaceuticals Inc. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual General Meeting Reco |
|
| March 6, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal execu |
|
| March 6, 2018 |
Clementia to Present at the Cowen and Company 38th Annual Health Care Conference EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Clementia to Present at the Cowen and Company 38th Annual Health Care Conference MONTREAL, March 06, 2018 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases, today announced that Clarissa Desjardins, Ph.D., c |
|
| February 28, 2018 |
EdgarFiling EXHIBIT 99.1 Clementia Reports 2017 Operating Results and Business Highlights Enrollment Underway in Palovarotene Phase 3 MOVE Trial for Fibrodysplasia Ossificans Progressiva (FOP) On-track to Enroll First Patient in Palovarotene Phase 2 MO-Ped Trial for Multiple Osteochondromas (MO) this Quarter MONTREAL, Feb. 28, 2018 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a |
|
| February 28, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal ex |
|
| February 28, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| February 28, 2018 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with this annual report on Form 20-F of Clementia Pharmaceuticals Inc. (the “Company”) for the fiscal year ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Clarissa Desjardins, President a |
|
| February 28, 2018 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with this annual report on Form 20-F of Clementia Pharmaceuticals Inc. (the “Company”) for the fiscal year ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael Singer, Chief Financial |
|
| February 28, 2018 |
Exhibit 12.1 CERTIFICATION I, Clarissa Desjardins, certify that: 1. 2. I have reviewed this annual report on Form 20-F of Clementia Pharmaceuticals Inc.; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleadin |
|
| February 28, 2018 |
Exhibit 12.2 CERTIFICATION I, Michael Singer, certify that: 1. 2. I have reviewed this annual report on Form 20-F of Clementia Pharmaceuticals Inc.; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading wit |
|
| February 14, 2018 |
CMTA / Clementia Pharmaceuticals Inc. / Bdc Capital Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Clementia Pharmaceuticals Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 185575107 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 8, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Clementia Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 185575107 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 7, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal ex |
|
| February 7, 2018 |
Clementia to Participate in Leerink Partners 7th Annual Global Healthcare Conference EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Clementia to Participate in Leerink Partners 7th Annual Global Healthcare Conference MONTREAL, Quebec, Feb. 07, 2018 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases, today announced that Clarissa Desjardin |
|
| January 31, 2018 |
EdgarFiling EXHIBIT 99.1 Clementia Appoints Industry Veteran Pierre Legault to its Board of Directors Accomplished Industry Leader Brings Over 35 Years of Experience in Advancing Biotechnology Companies MONTREAL, Jan. 31, 2018 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorde |
|
| January 31, 2018 |
CMTA / Clementia Pharmaceuticals Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal exe |
|
| January 29, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Clementia Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 185575107 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| January 26, 2018 |
EX-99.1 2 ss77035ex9901.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated January 25, 2018 (the “Schedule 13D”), with respect to the Common Shares of Clementia Pharmaceuticals, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchang |
|
| January 26, 2018 |
CMTA / Clementia Pharmaceuticals Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* CLEMENTIA PHARMACEUTICALS INC. (Name of Issuer) COMMON SHARES (Title of Class of Securities) 185575107 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP IV LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Addr |
|
| January 26, 2018 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated January 25, 2018 (the “Schedule 13D”), with respect to the Common Shares of Clementia Pharmaceuticals, Inc. |
|
| January 26, 2018 |
CMTA / Clementia Pharmaceuticals Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* CLEMENTIA PHARMACEUTICALS INC. (Name of Issuer) COMMON SHARES (Title of Class of Securities) 185575107 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP IV LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Addr |
|
| January 3, 2018 |
Clementia Announces Presentation at the J.P. Morgan 36th Annual Healthcare Conference EXHIBIT 99.1 Clementia Announces Presentation at the J.P. Morgan 36th Annual Healthcare Conference MONTREAL, Jan. 03, 2018 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases, today announced that Clarissa Desjardins, Ph.D., chief executive officer and foun |
|
| January 3, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal exe |
|
| December 12, 2017 |
EXHIBIT 99.1 Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva Patient Dosing Has Commenced; Registration Study to Enroll 80 Patients Worldwide Company to Host Conference Call at 8:30am ET Today MONTREAL, Dec. 12, 2017 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company inno |
|
| December 12, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2017 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal ex |
|
| December 5, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2017 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal ex |
|
| December 5, 2017 |
Clementia Announces Date of Corporate Update Conference Call EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Clementia Announces Date of Corporate Update Conference Call MONTREAL, Dec. 05, 2017 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company, today announced that management will host a conference call and webcast at 8:30 a.m. ET on Tuesday, Dec. 12, 2017, to provide a corporate update and discuss r |
|
| November 13, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2017 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal ex |
|
| November 13, 2017 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS EXHIBIT 99.1 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following management?s discussion and analysis (MD&A) of our financial condition and results of operations was prepared by Management with information available as at November 10, 2017. This MD&A should be read in conjunction with our unaudited interim condensed consolidated financial statements |
|
| November 13, 2017 |
Clementia Pharmaceuticals Inc. EXHIBIT 99.2 Clementia Pharmaceuticals Inc. Interim Condensed Consolidated Financial Statements Three and nine-month periods ended September 30, 2017 and 2016 (unaudited) Clementia Pharmaceuticals Inc. Interim Condensed Consolidated Statements of Financial Position (unaudited) As at (in US dollars) Note September 30, 2017 December 31, 2016 Assets Current assets Cash $ 37,238,196 $ 9,434,495 Short- |
|
| November 13, 2017 |
EXHIBIT 99.1 Clementia Reports Third Quarter 2017 Financial Results and Business Highlights Initial Public Offering Completed, Raising $128.2 Million in Net Proceeds U.S. FDA Grants Breakthrough Therapy Designation to Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP) On Track to Begin Pivotal MOVE Study in FOP Later this Year MONTREAL, Nov. 13, 2017 (GLOBE NEWSWIRE) - Clementia Pharmace |
|
| November 13, 2017 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2017 Commission File Number 001-38177 Clementia Pharmaceuticals Inc. (Translation of registrant?s name into English) 4150 St Catherine Street West, Suite 550 Montreal, Quebec, Canada, H3Z 2Y5 (Address |
|
| September 6, 2017 |
Clementia Pharmaceuticals to Participate in Upcoming Investor Conferences EXHIBIT 99.1 Clementia Pharmaceuticals to Participate in Upcoming Investor Conferences MONTREAL, Sept. 06, 2017 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical stage biopharmaceutical company, today announced that Dr. Clarissa Desjardins, CEO of Clementia Pharmaceuticals, will participate in two upcoming investor conferences: Morgan Stanley 15th Annual Global Healthcare |
|
| September 6, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2017 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal e |
|
| August 31, 2017 |
Clementia Announces Data Presentations at Upcoming Medical Conferences in September EXHIBIT 99.1 Clementia Announces Data Presentations at Upcoming Medical Conferences in September MONTREAL, Aug. 31, 2017 (GLOBE NEWSWIRE) - Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical stage biopharmaceutical company, today announced upcoming data presentations highlighting our palovarotene development efforts at the 2017 American Society for Bone and Mineral Research (ASBMR) Annual Me |
|
| August 31, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2017 Commission File Number: 333-219066 Clementia Pharmaceuticals Inc. (Translation of registrant's name into English) 4150 St Catherine Street West, Suite 550 (Address of principal exec |
|
| August 23, 2017 |
CMTA / Clementia Pharmaceuticals Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* CLEMENTIA PHARMACEUTICALS INC. (Name of Issuer) COMMON SHARES (Title of Class of Securities) 185575107 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP IV LLC Samuel D. Isaly 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739- |
|
| August 23, 2017 |
EX-99.1 2 ss56337ex9901.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated August 23, 2017 (the “Schedule 13D”), with respect to the Common Shares of Clementia Pharmaceuticals, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange |
|
| August 21, 2017 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2017 Commission File Number 001-38177 Clementia Pharmaceuticals Inc. (Translation of registrant?s name into English) 4150 St Catherine Street West, Suite 550 Montreal, Quebec, Canada, H3Z 2Y5 (Address of |
|
| August 21, 2017 |
Clementia Announces Closing of Over-Allotment Option in its Initial Public Offering Exhibit 99.1 Clementia Announces Closing of Over-Allotment Option in its Initial Public Offering Montreal, Quebec ? August 21, 2017 ? Clementia Pharmaceuticals Inc. (NASDAQ: CMTA) (the ?Company? or ?Clementia?), a clinical stage biopharmaceutical company, today announced that the underwriters of its previously announced initial public offering exercised their option to purchase an additional 1,191 |
|
| August 11, 2017 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS EXHIBIT 99.1 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following management?s discussion and analysis (MD&A) of our financial condition and results of operations was prepared by Management with information available as at August 9, 2017 and should be read in conjunction with our unaudited interim condensed consolidated financial statements for the th |
|
| August 11, 2017 |
Clementia Pharmaceuticals Inc. EXHIBIT 99.2 Clementia Pharmaceuticals Inc. Interim Condensed Consolidated Financial Statements Three and six -month periods ended June 30, 2017 and 2016 (unaudited) Clementia Pharmaceuticals Inc. Interim Condensed Consolidated Statements of Financial Position (unaudited) As at (in US dollars) Note June 30, 2017 December 31, 2016 Assets Current assets Cash $ 11,584,221 $ 9,434,495 Short-term inves |
|
| August 11, 2017 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2017 Commission File Number 001-38177 Clementia Pharmaceuticals Inc. (Translation of registrant’s name into English) 4150 St Catherine Street West, Suite 550 Montreal, Quebec, Canada, H3Z 2Y5 (Address of |
|
| August 11, 2017 |
CMTA / Clementia Pharmaceuticals Inc. / ORBIMED ADVISORS LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 CLEMENTIA PHARMACEUTICALS INC. (Name of Issuer) COMMON SHARES (Title of Class of Securities) 185575107 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP IV LLC Samuel D. Isaly 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Address |
|
| August 11, 2017 |
EX-99.1 2 ss54944ex9901.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated August 11, 2017 (the “Schedule 13D”), with respect to the Common Shares of Clementia Pharmaceuticals, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange |
|
| August 4, 2017 |
As filed with the Securities and Exchange Commission on August 4, 2017 As filed with the Securities and Exchange Commission on August 4, 2017 Registration No. |
|
| August 2, 2017 |
8,000,000 Shares Common Shares PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration No. 333-219066 8,000,000 Shares Common Shares Clementia Pharmaceuticals Inc. is offering 8,000,000 of its common shares. Prior to this offering, there had been no public market for our shares. Our common shares have been approved for listing on The Nasdaq Global Select Market under the symbol ?CMTA.? We are an ?emerging growth company? as de |
|
| August 2, 2017 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2017 Commission File Number 001-38177 Clementia Pharmaceuticals Inc. (Translation of registrant?s name into English) 4150 St Catherine Street West, Suite 550 Montreal, Quebec, Canada, H3Z 2Y5 (Address of |
|
| August 2, 2017 |
Clementia Announces Pricing of Initial Public Offering EX-99.1 3 c89065ex99-1.htm Exhibit 99.1 Clementia Announces Pricing of Initial Public Offering Montreal, Quebec – August 2, 2017 – Clementia Pharmaceuticals Inc. (NASDAQ: CMTA) (the “Company” or “Clementia”), a clinical stage biopharmaceutical company, today announced the pricing of its initial public offering of 8,000,000 common shares at an initial public offering price of $15.00 per share. The |
|
| August 1, 2017 |
As filed with the Securities and Exchange Commission on August 1, 2017 As filed with the Securities and Exchange Commission on August 1, 2017 Registration No. |
|
| August 1, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Clementia Pharmaceuticals Inc. |
|
| July 28, 2017 |
July 28, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street, N. |
|
| July 28, 2017 |
Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Leerink Partners LLC 299 Park Avenue, 21st Floor New York, New York 10176 July 28, 2017 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Clementia Pharmaceuticals Inc. Registration Statement on Form F-1 (File No. 333-219066) Acceleration Request Ladies and Gentlemen: As representatives of the |
|
| July 24, 2017 |
Memo to: Frank Wyman, SEC From: Clementia Pharmaceuticals Inc. Date: July 20, 2017 Subject: Response to inquiries about embedded derivatives Question 1 – What is management’s rationale for the Q1 2017 $44.8M increase in the Class A embedded derivative and the $9.5M decrease in the Class B embedded derivative? Also, explain the value shift concept between the classes. Background In accordance with |
|
| July 21, 2017 |
[?] Shares CLEMENTIA PHARMACEUTICALS, INC. COMMON SHARES UNDERWRITING AGREEMENT Exhibit 1.1 [?] Shares CLEMENTIA PHARMACEUTICALS, INC. COMMON SHARES UNDERWRITING AGREEMENT [?], 2017 [?], 2017 Morgan Stanley & Co. LLC Leerink Partners LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Leerink Partners LLC 299 Park Avenue, 21st Floor New York, New York 10176 Ladies and Gentlemen: Clementia Pharmaceuticals, Inc., a corporation incorporated under the Cana |
|
| July 21, 2017 |
Exhibit 10.11 INDEMNIFICATION AGREEMENT THIS AGREEMENT is made as of this [], B E T W E E N: CLEMENTIA PHARMACEUTICALS INC., a corporation incorporated under the Canada Business Corporations Act (the ?Corporation?) - and - [] (the ?Indemnified Party?) RECITALS: A. The Canada Business Corporations Act permits, and in some cases requires, the Corporation to indemnify individuals who are or were dire |
|
| July 21, 2017 |
Exhibit 10.10 Clementia pharmaceuticals INC. EMPLOYEE STOCK PURCHASE PLAN Article 1?Purpose This Employee Stock Purchase Plan (the ?Plan?) is intended to encourage share ownership by all eligible employees of Clementia Pharmaceuticals Inc. (the ?Company?), and each of its Participating Subsidiaries, so that they may participate in any future growth of the Company by acquiring or increasing their i |
|
| July 21, 2017 |
Exhibit 10.15 Amended and restated EMPLOYMENT AGREEMENT BETWEEN CLEMENTIA PHARMACEUTICALS USA INC. AND MR. JEFF PACKMAN MADE AS OF , 2017 1 EMPLOYMENT AGREEMENT THIS AGREEMENT made as of , 2017, B E T W E E N: CLEMENTIA PHARMACEUTICALS USA INC., a corporation incorporated under the laws of the state of Delaware, herein represented by Dr. Donna Grogan, President, duly authorized for the purposes he |
|
| July 21, 2017 |
Exhibit 10.16 AMENDed and restated EMPLOYMENT AGREEMENT BETWEEN CLEMENTIA PHARMACEUTICALS INC. AND MR. MICHAEL SINGER MADE AS OF , 2017 amended and restated EMPLOYMENT AGREEMENT THIS AGREEMENT is made as of , 2017, B E T W E E N: CLEMENTIA PHARMACEUTICALS INC., a corporation incorporated under the laws of Canada, having its head office at 4150 Sainte-Catherine Street West, Suite 550, Montreal, Que |
|
| July 21, 2017 |
Exhibit 10.8 CLEMENTIA PHARMACEUTICALS INC. THIRD AMENDED AND RESTATED STOCK OPTION PLAN [], 2017 ARTICLE 1 PURPOSE 1.1 Purpose The purpose of this Third Amended and Restated Stock Option Plan is to develop the interest and incentive of eligible employees, Directors, officers and Consultants of Clementia Pharmaceuticals Inc. (the ?Corporation?) or of its Affiliates, in the Corporation?s and its Af |
|
| July 21, 2017 |
Exhibit 10.12 AMENDED AND RESTATED EMPLOYMENT AGREEMENT BETWEEN CLEMENTIA PHARMACEUTICALS INC. AND DR. CLARISSA DESJARDINS MADE AS OF , 2017 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AGREEMENT made as of , 2017, B E T W E E N: CLEMENTIA PHARMACEUTICALS INC., a corporation incorporated under the laws of Canada, having its head office at 4150 Sainte-Catherine Street West, Suite 550, Montreal, Q |
|
| July 21, 2017 |
Exhibit 4.1 104598 INCORPORATED UNDER THE CANADA BUSINESS CORPORATIONS ACT CONSTITU?E SOUS L?AUTORIT? DE LA LOI CANADIENNE SUR LES SOCI?T?S PAR ACTIONS SEE REVERSE FOR CERTAIN DEFINITIONS VOIR AU VERSO POUR CERTAINES D?FINITIONS transferable on the books of the Company only upon surrender of this certificate properly endorsed. This certificate is not valid unless countersigned by the Transfer Agen |
|
| July 21, 2017 |
As filed with the U.S. Securities and Exchange Commission on July 20, 2017 As filed with the U.S. Securities and Exchange Commission on July 20, 2017 Registration no. 333-219066 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEMENTIA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Canada (State or other jurisdiction of incorporation or |
|
| July 21, 2017 |
Exhibit 3.2 BY-LAW a by-law relating generally to the transaction of the business and affairs of CLEMENTIA PHARMACEUTICALS INC. (the ?Corporation?) 1. DEFINITIONS AND PRINCIPLES OF INTERPRETATION 1.1 Definitions In this by-law and all other by-laws of the Corporation: (a) ?Act? means the Canada Business Corporations Act or any statute which may be substituted therefor, including the regulations th |
|
| July 21, 2017 |
Exhibit 3.1 SCHEDULE 2017-1 description of share capital The Corporation is authorized to issue an unlimited number of common shares and an unlimited number of preferred shares. The rights, privileges, restrictions and conditions attached to the said common shares and preferred shares are as follows: COMMON SHARES 1. Each holder of common shares shall be entitled to receive notice of and to attend |
|
| July 21, 2017 |
Exhibit 10.13 AMENDED AND RESTATED EMPLOYMENT AGREEMENT BETWEEN CLEMENTIA PHARMACEUTICALS USA INC. AND DR. DONNA ROY GROGAN MADE AS OF , 2017 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AGREEMENT made as of , 2017, B E T W E E N: CLEMENTIA PHARMACEUTICALS USA INC., a corporation incorporated under the laws of the state of Delaware, herein represented by Clarissa Desjardins, President and Chief |
|
| July 21, 2017 |
Exhibit 10.9 CLEMENTIA PHARMACEUTICALS INC. 2017 OMNIBUS INCENTIVE PLAN SECTION 1. PURPOSE The purpose of Clementia Pharmaceuticals Inc. 2017 Omnibus Incentive Plan (the ?Plan?) is to promote the interests of the Company and its shareholders by (i) attracting and retaining executive personnel and other key employees and directors of outstanding ability; (ii) motivating executive personnel and othe |
|
| July 21, 2017 |
Exhibit 10.14 Amended and restated EMPLOYMENT AGREEMENT BETWEEN CLEMENTIA PHARMACEUTICALS USA INC. AND MR. ERIC GRINSTEAD MADE AS OF , 2017 EMPLOYMENT AGREEMENT THIS AGREEMENT made as of , 2017, B E T W E E N: CLEMENTIA PHARMACEUTICALS USA INC., a corporation incorporated under the laws of the state of Delaware, herein represented by Dr. Donna Grogan, President, duly authorized for the purposes he |
|
| July 13, 2017 |
919 THIRD AVENUE NEW YORK NEW YORK 10022-3908 Martin C. Glass Tel +1 (212) 891-1672 [email protected] July 13, 2017 FOIA CONFIDENTIAL TREATMENT REQUEST The entity requesting confidential treatment is: Clementia Pharmaceuticals Inc. 4150 St. Catherine Street West, Suite 550 Montreal, Quebec, Canada H3Z 2Y5 CERTAIN PORTIONS OF THIS LETTER HAVE BEEN OMITTED FROM THE VERSION FILED VIA EDGAR. CONFIDENT |
|
| June 30, 2017 |
List of Subsidiaries of the Registrant EXHIBIT 21.1 List of Subsidiaries of the Registrant Clementia Pharmaceuticals USA Inc. |
|
| June 30, 2017 |
Exhibit 10.2 Confidential Information omitted and filed separately with the Securities and Exchange Commission. Five asterisks denote omissions. Execution Version Exclusive License Agreement Between Thomas Jefferson University And Clementia Pharmaceuticals, Inc. Re: [*****], titled “Muscle Repair and Regeneration Elicited by a Gamma-Retinoid Agonist” This Exclusive License Agreement between Thomas |
|
| June 30, 2017 |
Exhibit 16.1 Deloitte LLP La Tour Deloitte 1190 Avenue des Canadiens-de-Montr?al Suite 500 Montreal QC H3B 0M7 Canada Tel: 514-393-7115 Fax: 514-390-4111 www.deloitte.ca June 2, 2017 Securities and Exchange Commission 100 F Street, N.E. Washington DC 20549 U.S.A. We have read Clementia Pharmaceuticals Inc.?s statements under the section ?Change in Accountants? (the ?Section?) included in its Initi |
|
| June 30, 2017 |
Exhibit 10.5 Confidential Information omitted and filed separately with the Securities and Exchange Commission. Five asterisks denote omissions. Palovarotene Program Consultancy AGREEMENT between Clementia Pharmaceuticals Inc., 4150 Ste-Catherine St West, suite 550, Montreal Quebec H3Z 2Y5 Canada and Luca Sangiorgi, MD PhD Vicolo Malgrado 9, 40125 Bologna Italy PREAMBLE This Consultancy Agreement |
|
| June 30, 2017 |
Exhibit 10.1 Confidential Information omitted and filed separately with the Securities and Exchange Commission. Five asterisks denote omissions. License Agreement by and among F. Hoffmann-La Roche Ltd, a Swiss corporation; Hoffmann-La Roche Inc., a US corporation; and Clementia Pharmaceuticals Inc., a Canadian corporation 1. Definitions 2 2. Clementia Licenses 13 3. Roche?s Right to Negotiate 18 4 |
|
| June 30, 2017 |
As filed with the U.S. Securities and Exchange Commission on June 29, 2017 As filed with the U.S. Securities and Exchange Commission on June 29, 2017 Registration no. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEMENTIA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Canada (State or other jurisdiction of incorporation or organization) 2834 (Prim |
|
| June 30, 2017 |
COMMERCIAL SPONSORED RESEARCH AGREEMENT Exhibit 10.7 Confidential Information omitted and filed separately with the Securities and Exchange Commission. Five asterisks denote omissions. Sanford Burnham Prebys Medical Discovery Institute ? CONFIDENTIAL COMMERCIAL SPONSORED RESEARCH AGREEMENT THIS AGREEMENT is entered into this 21sr day of June, 2016 (the ?Effective Date?) by Sanford Burnham Prebys Medical Discovery Institute, a California |
|
| June 30, 2017 |
Exhibit 10.3 Confidential Information omitted and filed separately with the Securities and Exchange Commission. Five asterisks denote omissions. EXECUTION VERSION Confidential EXCLUSIVE LICENSE AGREEMENT Re: [*****], titled ?Therapeutic agent for keratoconjunctive disorders? [*****], titled ?Inhibitor for Retinochoroidal disorders? Patent application to be filed with internal filing number [*****] |
|
| June 30, 2017 |
Exhibit 10.4 Confidential Information omitted and filed separately with the Securities and Exchange Commission. Five asterisks denote omissions. Execution Version BY AND BETWEEN GALDERMA RESEARCH & DEVELOPMENT SNC and CLEMENTIA PHARMACEUTICALS INC. March 29, 2017 TABLE OF CONTENTS 1. DEFINITIONS 1 2. GRANT OF LICENSES; EXCLUSIVITY 15 2.1 Grant of Licenses to Clementia 15 2.2 Exclusivity 16 2.3 Add |
|
| June 30, 2017 |
Exhibit 10.6 Confidential Information omitted and filed separately with the Securities and Exchange Commission. Five asterisks denote omissions. AGREEMENT FOR FEE-PER-SERVICE This Agreement for fee-per-service (this ?Agreement?) is effective by and between Clementia Pharmaceuticals, Inc., a privately held biopharmaceutical company with an address at 4150 Sainte-Catherine St. West, Suite 550, Montr |
|
| June 30, 2017 |
Exhibit 4.2 EXECUTION COPY CLEMENTIA PHARMACEUTICALS INC. SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT March 16, 2017 TABLE OF CONTENTS Page Article 1 INTERPRETATION 2 1.1 Construction 2 1.2 Severability 3 1.3 Governing Laws 3 Article 2 CERTAIN DEFINITIONS 3 2.1 Definitions 3 Article 3 REGISTRATIONS 8 3.1 Demand Registrations 8 3.2 Short Form Registrations 12 3.3 Piggy-Back Registrati |
|
| June 29, 2017 |
919 THIRD AVENUE NEW YORK NEW YORK 10022-3908 919 THIRD AVENUE NEW YORK NEW YORK 10022-3908 June 29, 2017 Martin C. Glass Tel +1 (212) 891-1672 [email protected] Via EDGAR AND overnight courier Suzanne Hayes Assistant Director Office of Healthcare and Insurance United States Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Clementia Pharmaceuticals Inc. Registration Statement on Form F-1 Filed June 29, 2017 CIK No. |
|
| June 7, 2017 |
Exhibit 10.3 Confidential Information omitted and filed separately with the Securities and Exchange Commission. Five asterisks denote omissions. EXECUTION VERSION Confidential EXCLUSIVE LICENSE AGREEMENT Re: [*****], titled ?Therapeutic agent for keratoconjunctive disorders? [*****], titled ?Inhibitor for Retinochoroidal disorders? Patent application to be filed with internal filing number [*****] |
|
| June 7, 2017 |
Exclusive License Agreement Thomas Jefferson University Clementia Pharmaceuticals, Inc. Exhibit 10.2 Confidential Information omitted and filed separately with the Securities and Exchange Commission. Five asterisks denote omissions. Execution Version Exclusive License Agreement Between Thomas Jefferson University And Clementia Pharmaceuticals, Inc. Re: [*****], titled ?Muscle Repair and Regeneration Elicited by a Gamma-Retinoid Agonist? This Exclusive License Agreement between Thomas |
|
| June 7, 2017 |
Exhibit 16.1 Deloitte LLP La Tour Deloitte 1190 Avenue des Canadiens-de-Montr?al Suite 500 Montreal QC H3B 0M7 Canada Tel: 514-393-7115 Fax: 514-390-4111 www.deloitte.ca June 2, 2017 Securities and Exchange Commission 100 F Street, N.E. Washington DC 20549 U.S.A. We have read Clementia Pharmaceuticals Inc.?s statements under the section ?Change in Accountants? (the ?Section?) included in its Initi |
|
| June 7, 2017 |
COMMERCIAL SPONSORED RESEARCH AGREEMENT Exhibit 10.7 Sanford Burnham Prebys Medical Discovery Institute ? CONFIDENTIAL COMMERCIAL SPONSORED RESEARCH AGREEMENT THIS AGREEMENT is entered into this 21sr day of June, 2016 (the ?Effective Date?) by Sanford Burnham Prebys Medical Discovery Institute, a California not-for-profit public benefit corporation with an address at 10901 N. Torrey Pines Road, La Jolla, California 92037 (?Institute?) a |
|
| June 7, 2017 |
Exhibit 10.6 AGREEMENT FOR FEE-PER-SERVICE This Agreement for fee-per-service (this ?Agreement?) is effective by and between Clementia Pharmaceuticals, Inc., a privately held biopharmaceutical company with an address at 4150 Sainte-Catherine St. West, Suite 550, Montreal, Quebec, H3Z 2Y5, in the person of Clarissa Desjardins, PhD, CEO (?Clementia?), and Istituto Ortopedico Rizzoli, a public instit |
|
| June 7, 2017 |
Exhibit 10.5 Palovarotene Program Consultancy AGREEMENT between Clementia Pharmaceuticals Inc., 4150 Ste-Catherine St West, suite 550, Montreal Quebec H3Z 2Y5 Canada and Luca Sangiorgi, MD PhD Vicolo Malgrado 9, 40125 Bologna Italy PREAMBLE This Consultancy Agreement (“Agreement”) is made by and between Clementia Pharmaceuticals Inc., (hereinafter “CLEMENTIA”), having a principal place of business |
|
| June 7, 2017 |
Exhibit 10.4 Confidential Information omitted and filed separately with the Securities and Exchange Commission. Five asterisks denote omissions. Execution Version BY AND BETWEEN GALDERMA RESEARCH & DEVELOPMENT SNC and CLEMENTIA PHARMACEUTICALS INC. March 29, 2017 TABLE OF CONTENTS 1. DEFINITIONS 1 2. GRANT OF LICENSES; EXCLUSIVITY 15 2.1 Grant of Licenses to Clementia 15 2.2 Exclusivity 16 2.3 Add |
|
| June 7, 2017 |
List of Subsidiaries of the Registrant EXHIBIT 21.1 List of Subsidiaries of the Registrant Clementia Pharmaceuticals USA Inc. |
|
| June 7, 2017 |
This is a confidential draft submission to the U.S. Securities and Exchange Commission on June 6, 2017 and is not being filed under the Securities Act of 1933, as amended. Registration no. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEMENTIA PHARMACEUTICALS INC. (Exact name of Regi |
|
| June 7, 2017 |
Exhibit 10.1 Confidential Information omitted and filed separately with the Securities and Exchange Commission. Five asterisks denote omissions. License Agreement by and among F. Hoffmann-La Roche Ltd, a Swiss corporation; Hoffmann-La Roche Inc., a US corporation; and Clementia Pharmaceuticals Inc., a Canadian corporation 1. Definitions 2 2. Clementia Licenses 13 3. Roche?s Right to Negotiate 18 4 |
|
| June 6, 2017 |
919 THIRD AVENUE NEW YORK NEW YORK 10022-3908 June 6, 2017 Martin C. Glass Tel +1 (212) 891-1672 [email protected] Via EDGAR AND overnight courier Suzanne Hayes Assistant Director Office of Healthcare and Insurance United States Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Clementia Pharmaceuticals Inc. Amendment No. 1 to Confidential Draft Registration Statement on |
|
| April 19, 2017 |
Exclusive License Agreement Thomas Jefferson University Clementia Pharmaceuticals, Inc. Exhibit 10.2 Confidential Information omitted and filed separately with the Securities and Exchange Commission. Five asterisks denote omissions. Execution Version Exclusive License Agreement Between Thomas Jefferson University And Clementia Pharmaceuticals, Inc. Re: [*****], titled “Muscle Repair and Regeneration Elicited by a Gamma-Retinoid Agonist” This Exclusive License Agreement between Thomas |
|
| April 19, 2017 |
Exhibit 10.1 Confidential Information omitted and filed separately with the Securities and Exchange Commission. Five asterisks denote omissions. License Agreement by and among F. Hoffmann-La Roche Ltd, a Swiss corporation; Hoffmann-La Roche Inc., a US corporation; and Clementia Pharmaceuticals Inc., a Canadian corporation 1. Definitions 2 2. Clementia Licenses 13 3. Roche?s Right to Negotiate 18 4 |
|
| April 19, 2017 |
This is a confidential draft submission to the U.S. Securities and Exchange Commission on April 19, 2017 and is not being filed under the Securities Act of 1933, as amended. Registration no. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEMENTIA PHARMACEUTICALS INC. (Exact name of Registrant as specifi |
|
| April 19, 2017 |
CLEMENTIA PHARMACEUTICALS INC. Exhibit 4.2 EXECUTION COPY CLEMENTIA PHARMACEUTICALS INC. SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT March 16, 2017 TABLE OF CONTENTS Page Article 1 INTERPRETATION 2 1.1 Construction 2 1.2 Severability 3 1.3 Governing Laws 3 Article 2 CERTAIN DEFINITIONS 3 2.1 Definitions 3 Article 3 REGISTRATIONS 8 3.1 Demand Registrations 8 3.2 Short Form Registrations 12 3.3 Piggy-Back Registrati |
|
| April 19, 2017 |
Exhibit 10.3 Confidential Information omitted and filed separately with the Securities and Exchange Commission. Five asterisks denote omissions. EXECUTION VERSION Confidential EXCLUSIVE LICENSE AGREEMENT Re: [*****], titled “Therapeutic agent for keratoconjunctive disorders” [*****], titled “Inhibitor for Retinochoroidal disorders” Patent application to be filed with internal filing number [*****] |
|
| April 19, 2017 |
Exhibit 10.4 Confidential Information omitted and filed separately with the Securities and Exchange Commission. Five asterisks denote omissions. Execution Version BY AND BETWEEN GALDERMA RESEARCH & DEVELOPMENT SNC and CLEMENTIA PHARMACEUTICALS INC. March 29, 2017 TABLE OF CONTENTS 1. DEFINITIONS 1 2. GRANT OF LICENSES; EXCLUSIVITY 15 2.1 Grant of Licenses to Clementia 15 2.2 Exclusivity 16 2.3 Add |
|
| April 19, 2017 |
EX-10.5 25 filename25.htm Exhibit 10.5 CLEMENTIA PHARMACEUTICALS INC. Second AMENDED AND RESTATED STOCK OPTION PLAN JUNE 22, 2015 Article 1 PURPOSE 1.1 Purpose The purpose of this Second Amended and Restated Stock Option Plan is to develop the interest and incentive of eligible employees, Directors, officers and Consultants of Clementia Pharmaceuticals Inc. (the “Corporation”) or of its Affiliates |
|
| April 19, 2017 |
Exhibit 3.3 AMENDED AND RESTATED by-law no. 1 A by-law relating generally to the transaction of the business and affairs of clementia pharmaceuticals inc. JUNE 22, 2015 DIRECTORS 1. Calling of and notice of meetings. Meetings of the board will be held on such day and at such time and place as the President or Secretary of the Corporation or any two directors may determine. Notice of meetings of th |
